[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-stability-of-the-implants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-stability-of-the-implants":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100623034","thymoquinone-around-immediate-implant-100623034",false,"NCT07391384","Thymoquinone Around Immediate Implant","Evaluation of the Effect of Thymoquinone Hydrogel With Bone Graft in Comparison to Bone Graft Only Around Immediate Implant (Randomized Controlled Clinical Trials)","Thymoquinone","Inclusion Criteria:\n\n* 1- Patients ages more than 18 years old, Participants were chosen according to specific eligibility criteria, requiring them to be healthy individuals classified as ASA I by the American Society of Anesthesiologists.\n\n  2- Patients requiring extraction of posterior teeth with consequent immediate implant placement.\n\n  3- Indications for extraction included: non restorable teeth (posterior teeth), untreatable caries, endodontic failures, remaining roots, vertical fracture of the roots.\n\n  4- Natural teeth adjacent to the tooth to be extracted will required to have complete occlusal surfaces and be free from infections..\n\n  5\\. Patients will selected with a thick soft tissue phenotype and a minimum keratinized tissue width (KTW) of 2 mm.\n\nExclusion Criteria:\n\n* Pathologies or drugs that alter tissue integration with dental implants. 2- Head and neck radiation therapy. 3- Renal disease, bleeding disorders and anticoagulant therapy. 4- Pregnant females. 5- Patients with severe para-functional habits and unfavorable occlusion 6- Smokers. 7- Malaligned teeth and teeth with acute periapical pathosis.","ALL","20 Years","55 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"NA","use of Thymoquinone hydrogel with bone graft in comparison to bone graft only around immediate implant-this hydrogel fill the jumping zone in comparison to using hydrogel bone graft only to increase primary stability and enhance osseointegration",[28,29,30],"Immediate Dental Implant Placement","Jumping Gap","Primary Stability of the Implants",[32,33,34,35],"immediate implant","thymoquinone","hydrogel","bone graft","NOT_YET_RECRUITING","2026-01-29",{"date":39,"type":40},"2026-02-05","ACTUAL",{"date":42,"type":22},"2026-01-21",{"date":44,"type":22},"2026-04-11",{"name":46,"class":47},"shaimaa hamdy","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100566618","early-phase-1-osteoimplant-and-dental-implants-stability-100566618","NCT06657521","Osteoimplant and Dental Implants Stability","Influence of the Osteoimplant Vitamin Complex on the Stability of Dental Implants. Randomized Double-blind Clinical Trial.","OIMP","Inclusion Criteria:\n\n* Patients presenting with unitary or partial edentulism.\n\n  * Age: Between 18-75 years.\n  * Anaesthetic risk ASA I-II.\n  * Patients who do not abuse alcohol, drugs or chronic smoking (\\>10 cigarettes\u002Fday).\n  * Patients with adequate periodontal status (≤10% plaque index and bleeding index).\n  * Absence of drug allergies that could compromise our study.\n  * Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.\n  * Signed informed consent.\n\nExclusion Criteria:\n\n* Age not between 18-75 years old.\n* Pregnant or breastfeeding women.\n* Chronic smokers (\\>10 cigarettes\u002Fday).\n* Patients with decompensated metabolic disease.\n* Poor periodontal status (≥10% plaque index and bleeding index).\n* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.\n* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.\n* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.\n* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.\n* Patients with a history of renal colic.\n* Patients who are not going to undergo nephrotic colic.",true,"18 Years",{"count":59,"type":22},60,[61],"EARLY_PHASE1","Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows:\n\n'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.\n\nAs secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.\n\nThe sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:\n\n* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.\n* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.",[30,64],"Pain",[66,67,68,69,70,71],"Dental implant","vitamin c","vitamin D","stability","pain","inflamation","2024-10-23",{"date":74,"type":40},"2024-10-24",{"date":76,"type":22},"2025-01-01",{"date":78,"type":22},"2025-12-31",{"name":80,"class":47},"Universidad de Granada"]